Conditions: Non-small Cell Lung Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 40
Healthy volunteers: no

Brief summary:
This study is a single institution Phase II single arm trial to assess the efficacy of the combination of pevonedistat plus docetaxel in patients with previously treated advanced NSCLC (non-small cell lung cancer).

Detailed description:

Arms:
arm 1: Pevonedistat 25mg/m2 days 1, 3, 5 Docetaxel 75mg/m2 day 1 21 day cycle

Interventions: intervention 1: Pevonedistat intervention 2: Docetaxel
Intervention descriptions: intervention 1: 25mg/m2 days 1, 3, 5 intervention 2: 75mg/m2 day 1

Protocol document:
Prot_SAP_ICF_000.pdf: